Granulocytic sarcoma of Core-binding Factor (CBF) acute myeloid leukemia mimicking pancreatic cancer

References 

1. Jehn U, Suciu S, Thomas X, Lefrere F, Muus P, Berneman Z, et al. Non-infusional vs. intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia. 2006;10:1723–1730
2. Becker H, Pfeifer D, Duque-Afonso J, Nimer SD, Veelken H, Schwabe M, et al. Two cell lines of t(8;21) acute myeloid leukemia with activating c-KIT mutation: models for the “second hit” hypothesis. Leukemia 2008, in press.
3. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164–169
   • Abstract
   • Full Text
   • Full-Text PDF (108 KB)
   • CrossRef
4. Peterli R, Meyer-Wyss B, Herzog U, Tondelli P. CA19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr. 1999;129:777–779
5. Piccaluga PP, Ascani S, Agostinelli C, Paolini S, Laterza C, Papayannidis C, et al. Myeloid sarcoma of liver: an unusual cause of jaundice. Report of three cases and review of literature. Histopathology. 2007;50:802–805
   • MEDLINE
   • CrossRef
6. Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15:466–475
7. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904–3911
8. Advani AS, Rodriguez C, Jin T, Jawde RA, Saber W, Baz R, et al. Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res. 2008;32:913–918
   • Abstract
   • Full Text
   • Full-Text PDF (248 KB)
   • CrossRef
9. Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108:3280–3288
   • MEDLINE
   • CrossRef
10. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24:2480–2489
    • CrossRef
11. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7:1268–1274
12. Deschler B, de Witte T, Mertelsmann R, Lübbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006;91:1513–1522
13. Grimwade D, Moorman A, Hills R, Wheatley K, Walker H, Harrison G, et al. NCRI Adult Leukaemia Working Party Impact of karyotype on treatment outcome in acute myeloid leukaemia. Ann Hematol 2004; 83:S45–8.
14. Knipp S, Hildebrand B, Kündgen A, Giagounidis A, Kobbe G, Haas R, et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer. 2007;110:345–352
    • CrossRef
15. Krug U, Serve H, Müller-Tidow C, Mesters RM, Steffen B, Büchner T, et al. New molecular therapy targets in acute myeloid leukemia. Recent Res Cancer Res. 2007;176:243–262